BullFrog AI has announced the formation of a new commercial leadership team aimed at driving growth for its AI-driven drug discovery platform.
The company, based in Gaithersburg, Maryland, is leveraging the expertise of seasoned executives to enhance its commercial strategy and expand its market presence. The newly appointed leaders include John Stewart as SVP of Commercial Sales, Eric Roos as SVP of Business Development & Corporate Strategy, and Tom Hazel, Ph.D., as VP of Scientific Operations. Each brings extensive experience in technology sales, biotech innovation, and drug development, which aligns with BullFrog AI's goal of optimizing its integrated pharmaceutical AI platform.
Stewart has over 25 years in enterprise IT sales, known for scaling revenue and aligning commercialization strategies. Roos, with more than 30 years in biotech, focuses on corporate strategy and partnerships, while Hazel has a strong background in scientific operations and drug discovery. Together, they are expected to strengthen BullFrog AI's capabilities in driving revenue growth and fostering strategic collaborations.
Vin Singh, the company's founder and CEO, emphasized that these appointments reflect BullFrog AI's commitment to long-term growth and innovation in drug discovery. By enhancing their commercial infrastructure, the company aims to streamline data preparation and analytics, ultimately improving therapeutic development and reducing clinical trial failure rates. This strategic move positions BullFrog AI to capitalize on emerging opportunities in the pharmaceutical landscape.